Xencor, Inc. (NASDAQ:XNCR) Receives $35.75 Consensus PT from Brokerages

Xencor, Inc. (NASDAQ:XNCR) has earned an average rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $35.75.

XNCR has been the subject of several recent analyst reports. Royal Bank of Canada upped their target price on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 price objective (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Wedbush reiterated an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th.

Insider Activity

In related news, VP John R. Desjarlais sold 68,684 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bassil I. Dahiyat sold 3,366 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total value of $80,851.32. Following the sale, the chief executive officer now owns 352,615 shares of the company’s stock, valued at approximately $8,469,812.30. The trade was a 0.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.23% of the company’s stock.

Hedge Funds Weigh In On Xencor

A number of institutional investors and hedge funds have recently modified their holdings of XNCR. Point72 Asset Management L.P. grew its stake in shares of Xencor by 147.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after buying an additional 1,858,440 shares during the period. Darwin Global Management Ltd. acquired a new stake in Xencor in the first quarter valued at approximately $24,557,000. Logos Global Management LP increased its holdings in shares of Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after acquiring an additional 850,000 shares in the last quarter. RA Capital Management L.P. acquired a new position in shares of Xencor during the third quarter worth approximately $11,563,000. Finally, RTW Investments LP bought a new position in shares of Xencor in the 3rd quarter worth $11,563,000.

Xencor Stock Up 3.8 %

XNCR stock opened at $25.01 on Wednesday. Xencor has a 52 week low of $15.31 and a 52 week high of $26.84. The business has a 50-day simple moving average of $21.40 and a 200 day simple moving average of $20.41. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.75 billion, a PE ratio of -7.55 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.27. The company had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business’s revenue for the quarter was down 81.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) EPS. Sell-side analysts anticipate that Xencor will post -3.71 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.